CIP
ACAD icon

Chartwell Investment Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Chartwell Investment Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20,845
Closed -$1.01M – 413
2020
Q2 		$1.01M Sell
20,845
-7,601
-27% -$365K 0.04% 330
2020
Q1 		$1.2M Buy
28,446
+3,205
+13% +$132K 0.06% 305
2019
Q4 		$1.08M Sell
25,241
-24,759
-50% -$1.08M 0.04% 353
2019
Q3 		$1.8M Buy
+50,000
New +$1.52M 0.06% 324

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Chartwell Investment Partners's ACAD Position: Q3 2020 in Review

Chartwell Investment Partners sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 20,845 shares — an estimated $1.01M sold.

Chartwell Investment Partners first reported a position in ACAD in Q3 2019 and held it in 4 quarters. The position peaked at $1.8M in Q3 2019. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

  • Chartwell Investment Partners reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Chartwell Investment Partners sold 20,845 Acadia Pharmaceuticals shares in Q3 2020, an estimated $1.01M.
  • Chartwell Investment Partners first reported a position in Acadia Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • Chartwell Investment Partners's Acadia Pharmaceuticals position peaked at $1.8M in Q3 2019.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Chartwell Investment Partners's 13F filing for Q3 2020, filed 16 Nov 2020.